Overexpression of E2F5/p130, but not E2F5 alone, can inhibit E2F-induced cell cycle entry in transgenic mice

Qin Chen,¹ Dongcai Liang,² Paul A. Overbeek²

¹College of Optometry, University of Houston, Houston, TX; ²Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX

Purpose: The retinoblastoma (Rb) gene family member p130 binds preferentially to the E2F5 transcription factor and forms a repressive E2F5/p130 complex that inhibits cell cycle progression and tumor growth. It is unclear whether E2F5, either alone or in combination with p130, can interfere with the transcriptional activity of other E2F family members, such as E2F1 and E2F3a, in vivo. In this study, we used transgenic mice to test whether overexpression of E2F5 with/without p130 would be sufficient to inhibit E2F1 or E2F3a induced cell cycle reentry.

Methods: Transgenic mice were generated by microinjection of constructs containing different E2F cDNAs (E2F1, E2F3a, and E2F5) or the p130 cDNA linked to the mouse αA-crystallin promoter. The E2F5 single and E2F5/p130 double transgenic mice were cross-mated with E2F1 or E2F3a transgenic mice. The resulting double or triple transgenic mouse embryos were characterized by histology, in situ hybridization, immunohistochemistry, and BrdU incorporation assays.

Results: Overexpression of E2F5 alone was not sufficient to inhibit E2F1 or E2F3a induced cell cycle reentry in lens fiber cells. Transgenic mice coexpressing E2F5 and p130 in lens fiber cells did not show lens defects. However, coexpression of E2F5/p130 with E2F1 or E2F3a in lens fiber cells decreased the number of BrdU positive fiber cells induced by the E2F1 or E2F3a alone. Therefore, overexpression of E2F5/p130, but not E2F5 alone, can inhibit activator E2F-mediated cell proliferation in vivo, confirming that p130 plays a critical role in the repressive activity of E2F5/p130 complex.

Conclusions: Overexpression of E2F5/p130 in post-mitotic lens fiber cells does not affect their normal differentiation program, but can inhibit inappropriate cell cycle reentry induced by the activator E2Fs. Since E2F5 alone cannot interfere with these E2F activities, we conclude that p130 is a key player in the inhibitory process.

The retinoblastoma gene family of tumor suppressors includes three members pRb (Rb1), p107 (RbL1) and p130 (Rb2). Because the main region of sequence similarity between these proteins resides in a pocket domain, they are often referred to as the “pocket proteins” [1]. These proteins play important roles in many aspects of development, particularly in the regulation of cell cycle progression. Although they share many biochemical similarities and have extensive functional overlap, these pocket proteins are not equivalent. For example, in humans, a germ-line mutation of the Rb1 gene can lead to development of retinoblastoma, a highly malignant intra-ocular tumor that arises in the neural retina of infant eyes. Unlike the Rb1 gene, the gene encoding p130 is located in chromosome 16q12.2, and deletions in this area are related to several human cancers including prostate, breast, and ovarian cancers [2]. In mice, Rb1 null embryos die around day 13 of gestation with defects in placental, erythroid, neuronal, and lens development [3,4]. In contrast, mice deficient in p107 or p130 develop normally and exhibit no overt adult phenotypes [5]. The tumor suppressive properties of these pocket proteins are known to be dependent upon their ability to bind to the E2F family of transcription factors and to form a repressive Rb-E2F complex [6-8].

There are currently nine E2F genes (E2F1, E2F2, E2F3a, E2F3b, E2F4, E2F5, E2F6, E2F7, and E2F8) identified in mammals [9,10]. Based on their functional considerations, these E2F proteins can be classified into either “activators” (E2F1, E2F2, and E2F3a) or “repressors” (E2F3b, E2F4, E2F5, E2F6, E2F7, and E2F8). The activator E2Fs contain a nuclear localization signal (NLS) and are predominantly in the nucleus. They bind with high affinity to pRb, and their expression is highly upregulated in late G1 of the cell cycle. Ectopic expression of any of them is sufficient to induce G1/S transition and cell proliferation [9-13]. In contrast, the repressors E2F4 and E2F5 do not have such an NLS domain, therefore, are primarily in the cytoplasm. These two E2Fs bind with high affinity to the pRb homologs, p107 and p130 [8-10]. They are mainly expressed in quiescent cells, and can activate transcription only under some circumstances [9,10,14,15]. The members of E2F6, E2F7, and E2F8, do not have a pocket protein interaction domain and are believed to repress transcription of specific promoters [9,10]. The complexity of the E2F family suggests that individual E2F proteins play distinct roles in the regulation of cell proliferation, as described by our previous
observations and many studies from others [9-11,13-15]. However, it is not yet clear whether individual E2Fs could interact with each other. The pRb homolog p130 is thought to be a tumor suppressor, and overexpression of p130 can inhibit cell proliferation by forming a strong repressive complex with E2F4 and E2F5 [2,9,16-20]. Knockout studies showed that E2F4 and E2F5 are necessary for the pocket protein-mediated G₁ control of the cell cycle, because mouse embryonic fibroblasts (MEFs) deficient for these two E2Fs are unable to exit the cell cycle in response to p16INK4a [21]. However, so far, there is no in vivo evidence showing that extra E2F4 or E2F5, in the absence or presence of extra p130, can interfere with the activities of activator E2Fs. Here, we test whether overexpression of E2F5 with or without p130 is sufficient to repress cell cycle reentry induced by activator E2Fs in postmitotic lens fiber cells.

The embryonic lens of the eye is an attractive model system for studying the molecular mechanisms that regulate cell proliferation and differentiation. The lens is composed of two cell types: anterior proliferative epithelial cells and
posterior terminally differentiated, post-mitotic, elongated fiber cells [22]. Lens epithelial cells at the bow region are stimulated to exit from cell cycle and to differentiate into fiber cells. Almost all E2F family members are expressed in lens epithelial cells, while only E2F1, E2F3 and E2F5 are detected in post-mitotic lens fibers [23]. pRb and p107 proteins were detected in both lens epithelial and fiber cells [23]. Since p130/E2F complexes were not detected in lens fiber cells, it was proposed that pRb and p107 are the primary regulators of E2F activities in differentiating lens fiber cells [23]. Previous studies have shown that inactivation of pRb by targeted mutagenesis of the Rb gene, or by expression of viral proteins,
results in inappropriate cell cycle reentry in lens fiber cells [24-27]. The activator E2Fs, particularly E2F3, make a major contribution toward the in vivo phenotypic consequences of pRb deficiency [28]. Although both E2F5 and p130 are considered to play important roles in the regulation of cell cycle exit and terminal differentiation, it is not known whether elevated levels of E2F5 in combination with p130 would be able to alter lens fiber cell differentiation program.

In this study, we have generated double transgenic mice with lens-specific coexpression of E2F5 with E2F1 or E2F3a. We have also generated transgenic mice coexpressing E2F5 with p130 in the lens fiber cells, and triple transgenic mice coexpressing E2F5/p130 with E2F1 or E2F3a. We found that overexpression of E2F5/p130 in the lens fiber cells did not alter normal fiber cell differentiation. Overexpression of E2F5 alone was not sufficient to repress inappropriate cell cycle entry induced by E2F1 or E2F3a. However, cell cycle reentry was significantly inhibited by overexpression of E2F5/p130.

**METHODS**

*Generation of the constructs and transgenic mice:* All animals were used in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Human E2F1, Myc-tagged mouse E2F3a and human E2F5 transgenic lines were generated as previously described [15,29]. E2F5/p130 double transgenic mice were generated by coinjection. A Sac II – Xba I fragment containing the human E2F5 cDNA and a Cla I – EcoR V fragment carrying mouse p130 cDNA were cloned downstream from the δenhancer/αA-crystallin promoter in the vector δenαA-minx (DREAM) [30]. The resultant plasmids (Figure 1A) were digested with KpnI and NotI to release fragments for microinjection. The fragments were separated by electrophoresis through a 1.2% agarose gel and purified using a Qiaex II gel extraction kit (Qiagen, Hilden, Germany). Transgenic mice were generated by pronuclear coinjection of both fragments into one-cell-stage inbred FVB/N embryos [31,32]. Two stable transgenic families (OVE1811 and OVE1812) expressing both E2F5 and p130 transgenes were generated from the coinjection. E2F5 single (OVE1598) and E2F5/p130 double (OVE1811) transgenic mice were cross-mated with E2F1 (OVE527) or E2F3a (OVE1728) transgenic mice to generate double (E2F5/E2F1 or E2F5/E2F3a) and triple (E2F5/p130/E2F1 or E2F5/p130/E2F3a) transgenic mice.

*Screening of transgenic mice:* Genomic DNA from mouse tails was isolated as previously described [31]. For polymerase chain reaction (PCR) screening of E2F1, E2F3a, and E2F5 single transgenic mice, sense (5’-GTG AAG GAA CCT TAC TTC TGT GGT G) and antisense (5’-GTC CTT GGG GTC TTC TAC CCT TTC TC) primers specific to the simian virus (SV) 40 sequences in CPV2 were used to amplify a ~300 bp fragment. To screen for the E2F5 and p130 transgenes driven by the δenhancer/αA-crystallin (DREAM) promoter, we used the following primers: 1) minx sense: 5’-GTC TTT CCA GTG GGG ATG CTC T-3’; 2) E2F5 antisense: 5’-TCC TGC AGC AGC GAC GAC AA-3’; 3)
p130 antisense: 5′-GCT GCT GGA TCT GAT GGC TC-3′. A ~400 bp fragment was amplified by the minx/E2F5 or minx/p130 primers. PCR assays were performed as described previously [29].

**Lens histology:** Female transgenic mice were superovulated and mated with male transgenic mice. The presence of a vaginal plug was defined as gestational day 0.5. Embryonic heads at embryonic day (E) 14.5 and 15.5 were fixed in 10% formalin, paraffin embedded, cut into 5-μm thick sections, and stained with hematoxylin and eosin by standard techniques.

**In situ hybridization:** In situ hybridization was performed using 35S-labeled riboprobes, as described in Fromm and Overbeek [33]. An SV40-specific riboprobe and the probes for E2F1, E2F3a, and E2F5 were described previously [15, 29]. A riboprobe for mouse p130 was generated from plasmid p130/pBluscript. Hybridization signals were initially captured as dark-field images. For some of the figures, the dark-field images were pseudo-colored red, then superimposed on bright-field images of the same tissue section (counterstained by hematoxylin) using image analysis software (Photoshop; Adobe, San Diego, CA).

**BrdU Incorporation:** DNA replication was detected by 5-bromo-2′-deoxyuridine (BrdU) incorporation. BrdU (100 μg/g bodyweight; Sigma-Aldrich Co., St. Louis, MO) was injected into pregnant female mice. One hour later, the mice were sacrificed and embryos were analyzed by immunohistochemistry as described previously [25]. For quantification, the tissue slides containing mid-frontal lens sections were selected for BrdU staining, and the number of BrdU-positive nuclei in lens fiber cells was counted and compared with the total number of nuclei in the same region, determined by hematoxylin staining. Results are the mean ± SD from four individual tissue slides (each slide was from different transgenic tissue block and contained at least 3 eye sections). Statistical analyses were performed with two-tailed Student's t-tests using Microsoft Excel software. Data were considered to be significantly different for p<0.05.

**Immunohistochemistry:** Tissue sections were deparaffinized in xylene and rehydrated through a graded alcohol series, washed with PBS, and incubated with 10% methanol/3% hydrogen peroxide in PBS to block endogenous peroxidase.

---

**Table 1. Percentage of BrdU positive lens fiber cells.**

| Transgenic families | BrdU* (%) |
|---------------------|-----------|
| E2F1                | 42±1.6    |
| E2F3a               | 10±1.2    |
| E2F5                | 0         |
| E2F1/E2F5           | 44±1.8    |
| E2F3a/E2F5          | 10±1.3    |
| E2F5/p130           | 0         |
| E2F5/p130/E2F1      | 8±0.8     |
| E2F5/p130/E2F3a     | 5±0.5     |

The sharp (hash mark) shows the percentage of positive cells: the number of brown nuclei in lens fiber cells compared with the total number of fiber cell nuclei.

---

Figure 4. Characterization of E2F3a/E2F5 double transgenic eyes at E15.5. A, B: Expression of E2F3a and E2F5 transgenes was confirmed by in situ hybridizations with E2F3a and E2F5 riboprobes. Hybridization signals were captured as dark-field images. The E2F3a (A) and E2F5 (B) transgenes were specifically expressed in lens fiber cells, as described previously [15]. C: Ocular histology of the E2F3a/E2F5 double transgenic lenses showed modest alterations in fiber cell elongation and the presence of extra nuclei in the center of the lens. D: The same percentage of fiber cells were BrdU positive in the double transgenic lens as in the E2F3a single transgenic lens described previously (Table 1) [15]. Scale bars=500 μm.
activity. Slides were boiled in 10 mM sodium citrate buffer (pH 6.0) for 20 min using a microwave oven, and then incubated with 10% normal horse serum for 1 h at 37 °C. For detection of E2F5, p130, and Myc-tagged E2F3a transgenic proteins, primary antibodies against E2F5 (Santa Cruz Biotechnology, Santa Cruz, CA), p130 (Sigma-Aldrich Co.), or Myc (Sigma-Aldrich Co.) were used at a 1:500 dilution in 10% normal horse serum in PBS, with incubation at 4 °C for 24 h. The slides were washed with PBS (4 × 5 min), and a secondary antibody (1:200; biotin-conjugated anti-rabbit or anti-mouse IgG; Vector Laboratories, Burlingame, CA) was added for 1 h at room temperature. After washing 4 times with PBS, ExtrAvidin-fluorescein isothiocyanate conjugate (Sigma-Aldrich Co.) was added and incubated for 1 h at room temperature, followed by PBS washes. The slides were mounted with Aqua-Poly/Mount (Vector Laboratories).

RESULTS

Overexpression of E2F5 does not affect E2F1-induced cell cycle reentry: In our previous studies, we generated transgenic mice specifically expressing E2F1 or E2F5 in lens fiber cells [15,29]. At E15.5, the E2F1 lenses (OVE527 and OVE530) showed severe defects in fiber cell elongation and alignment. At the posterior of these transgenic lenses, there were many extra nuclei which incorporated BrdU indicative of inappropriate cell cycle reentry, and many condensed fiber nuclei indicative of apoptosis [29]. By comparison, the transgenic mice in each E2F5 family (OVE1598 and OVE1599) showed a normal eye phenotype, and there were no extra BrdU positive nuclei in the E2F5 expressing lens fiber cells [15]. Since E2F5 is thought to be a cell cycle “repressor,” we tested whether overexpression of E2F5 was sufficient to inhibit the E2F1-induced cell cycle reentry. Homozygous E2F1 mice (OVE527) were cross-mated with E2F5 transgenic mice (OVE1598) to generate E2F1/E2F5 double transgenic mice. To confirm expression of transgenes, in situ hybridization was performed using riboprobes for human E2F1 or E2F5. At E14.5, transcripts of the endogenous E2F1 and E2F5 were detected in non-transgenic FVB lens epithelial and corneal cells (Figure 2C,G), suggesting that these human E2F1 and E2F5 riboprobes cross-reacted to the mouse E2F1 and E2F5 transcripts. Endogenous E2F5, but not E2F1, was also detectable in the FVB lens fiber cells (Figure 2C,G). By comparison, E2F1 and E2F5 transgenes were highly expressed in the double transgenic fiber cell nuclei (Figure 2B,D,F,H). The double transgenic lenses showed defects in fiber cell elongation (Figure 2B), and many BrdU positive lens fiber cells (Figure 3D). The percentage of BrdU positive fiber cells between E2F1 single and E2F1/E2F5 double transgenic lenses was not significant (p>0.05; Table 1). Therefore, overexpression of E2F5 alone is not sufficient to repress E2F1-induced cell cycle reentry.

Overexpression of E2F5 does not affect E2F3a-induced cell cycle reentry: E2F3a transgenic mice have small eyes and cataracts, similar to the E2F1 transgenic mice with BrdU positive fiber nuclei and enhanced programmed cell death [15,29]. To determine whether overexpression of E2F5 could...
alter the E2F3a phenotype, E2F3a transgenic mice (OVE1728) were cross-mated with the E2F5 transgenic mice (OVE1598) to generate the E2F3a/E2F5 double transgenic mice. At E15.5, in situ hybridization revealed that both transgenes were expressed in lens fiber cells, and that E2F5 was more highly expressed at the RNA level (Figure 4A,B). Lens morphology and the number of BrdU positive fiber cells in the E2F3a/E2F5 double transgenic lenses were similar to that seen in the E2F3a single transgenic lenses (p>0.05; Figure 4C,D;Table 1) [15]. To verify expression of both transgenic proteins, immunohistochemistry was performed using anti-Myc antibody for the E2F3a and anti- E2F5 for the E2F5 transgene. As shown in Figure 5, there was no staining for Myc-tagged protein in the non-transgenic lens (Figure 5A). By comparison, intensive green nuclear staining was seen in the triple transgenic lens fiber cells for all three proteins (C, G, K). Cell nuclei were visualized by DAPI staining (B, D, F, H, J, L). Scale bars=500 μm.

Generation of E2F5/p130 double transgenic mice: The pRB homolog p130 is a binding partner of E2F5. It has been known that overexpression of p130 can lead to a G1 cell cycle arrest in cultured cells [34]. Since E2F5 and p130 complex are thought to be important in the regulation of cell cycle exit and terminal differentiation, we wanted to test whether coexpression of E2F5 and p130 would be able to alter normal lens fiber cell differentiation. To generate transgenic mice expressing both E2F5 and p130, we co-injected DREAM-E2F5 and DREAM-p130 constructs (Figure 1A). Two stable bigenic families (OVE1811 and OVE1812) were obtained from the coinjection. Mice in both families showed a normal eye phenotype.

Overexpression of E2F5/p130 does not affect normal lens fiber cell differentiation: The lens morphology in the E2F5/p130 double transgenic embryos at E15.5 was similar to that seen in nontransgenic or E2F5 only transgenic lenses (Figure 1B) [15]. There was no BrdU incorporation detected in the bigenic lens fiber cells (Figure 1C). In situ hybridization revealed that transcripts of E2F5 and p130 were present specifically in the transgenic lens fiber cells (Figure 1D,E). A previous study showed that E2F/p130 complexes were undetectable in rat lens fiber cells, probably due to degradation of the p130 protein by ubiquitination [23]. To test
the presence of p130 and E2F5 transgenic proteins, immunohistochemistry was performed using antibodies against p130 and E2F5. In the nontransgenic FVB lens, shown in the next section, there was no staining for p130 protein in fiber cells (Figure 6I), consistent with the previous observation [23]. By comparison, both p130 and E2F5 protein staining are present in lens fiber cell nuclei of the double transgenic mice (Figure 1F,G).

Expression of E2F5/p130 decreases E2F3a-induced cell cycle reentry: Hypophosphorylated p130 forms a repressor complex with the E2F4, which can block E2F-responsive promoter sites, and can inhibit the G1/S transition of the cell cycle [18-20]. We hypothesized that the E2F5/p130 complex could also function as a cell cycle repressor in vivo. To examine whether coexpression of E2F5 and p130 can inhibit cell proliferation induced by E2F3a, E2F3a transgenic mice (family OVE1728) were cross-mated with the E2F5/p130 double transgenic mice (OVE1811) to generate triple transgenic mice. At E15.5, when compared to nontransgenic FVB lenses (Figure 7A,D), the E2F3a single transgenic lenses showed defects in fiber cell elongation and BrdU positive fiber cells (Figure 7B,E) [15]. The triple transgenic lenses showed less severe pathology (Figure 7C). Although condensed fiber cell nuclei were still present in the center of the triple transgenic lens (Figure 7C), the number of BrdU positive fiber nuclei was decreased by about 50% (p<0.01; Figure 7F; Table 1). Immunohistochemistry showed staining for Myc-tagged E2F3a, E2F5 and p130 proteins in most of the triple transgenic lens fiber cell nuclei (Figure 6C,G,K) when compared to the non-transgenic FVB lenses (Figure 6A,E,I), confirming the expression of these transgenic proteins.

Expression of E2F5/p130 inhibits E2F1-induced cell cycle reentry: To test whether coexpression of E2F5 and p130 could also inhibit E2F1-induced cell cycle reentry, E2F1 transgenic mice (family OVE527) were cross-mated with the E2F5/p130 double transgenic mice from family OVE1811 to generate triple transgenic mice. At E15.5, the triple transgenic lenses still showed defects in fiber cell elongation and alignment, although slightly less severe than the E2F1 single transgenic lenses (Figure 8A,B) [29]. Condensed fiber cell nuclei were still present in the center of the triple transgenic lens (Figure 8B), indicating that these cells were undergoing programmed cell death. However, the number of BrdU positive fiber cell nuclei in the triple transgenic lenses was decreased by 80% (p<0.01; Figure 8C,D;Table 1) [29], suggesting that E2F5/p130 expression causes a dramatic reduction in E2F1 activity. The expression of E2F1, E2F5 and p130 transgenes in the triple transgenic lens fiber cells was confirmed by in situ hybridization (Figure 9). When compared to the intensity of
E2F1 or E2F5 transcription signals (Figure 9B,D), the level of p130 transgene expression was low (Figure 9F).

**DISCUSSION**

E2F4 and E2F5 are thought to be cell cycle repressors as E2F4−/− and/or E2F5−/− cells are unable to exit the cell cycle in response to p16INK4A [21]. Our previous transgenic studies demonstrated that E2F4 can function as a weak cell cycle activator and can induce cell cycle reentry in post-mitotic lens fiber cells [15]. In this study, we have expressed E2F5, with/without p130, together with E2F1 or E2F3a in the ocular lens of transgenic mice to assess the prediction that E2F5 can inhibit or repress cell cycle progression. Our results indicate that overexpression of E2F5 alone was not sufficient to inhibit cell cycle reentry induced by the cell cycle activators E2F1 and E2F3a. Bicogenic expression of E2F5 and p130 in lens fiber cells did not affect normal fiber cell differentiation. However, overexpression of E2F5 and p130 provided 50–80% inhibition of E2F1 or E2F3a induced cell cycle entry. Our transgenic studies provide in vivo evidence that E2F5/p130 can function as a cell cycle repressor and can inhibit cell proliferation. Our studies do not address the issue of whether p130 alone can inhibit cell cycle reentry induced by E2F1–3, or whether this inhibition requires formation of a p130-E2F5 complex.

**E2F5 alone does not repress cell cycle progression:**

When the pRb family members are phosphorylated and dissociated from the E2Fs, the free E2F4 and E2F5 proteins move to the cytoplasm, while the activator E2F proteins (E2F1, E2F2, and E2F3a) bind to the E2F-responsive gene promoters that are vacated by E2F4 and E2F5, even though at some promoters their binding sites may be different [35,36]. We have shown that expression of E2F1–4 in ocular lens fiber cells can upregulate E2F target genes and induce post-mitotic lens fiber cells to re-enter the cell cycle [15,29]. In this study, we used the same transgenic approaches to test whether extra E2F5 could interfere with the activator E2Fs. We found that overexpression of E2F5 in fiber cells was not sufficient to disrupt S phase induction by E2F1 or E2F3a.

**Generation of E2F5/p130 double transgenic mice:**

Since extra “free” E2F5 did not interfere with the activator E2Fs, we hypothesized that the role of repressor E2Fs might be dependent upon their binding partners, the pocket proteins. Since E2F5 is believed to bind preferentially to p130 [8], we used the δenαA-minx promoter (DREAM) vector for E2F5 and p130 cDNA constructs to generate E2F5/p130 double transgenic mice. This modified αA-crystallin promoter has been shown to be active in both lens epithelial and fiber cells [30]. However, among transgenic mice (OVE1811 and OVE1812) that were obtained from our micro-coinjection, we found that both E2F5 and p130 transgenes were mainly expressed in lens fiber cells, with little or no expression in lens epithelial cells (Figure 1). Inactivation of DREAM promoter in lens epithelial cells might be due to different transgene integration site, or repressive interaction between E2F5 and p130 transgenes.

**E2F5/p130 does not affect normal lens fiber differentiation, but inhibits deregulated cell cycle**
Expression of E2F4 and E2F5 is found mainly present in quiescent cells at G0, and is thought to be important for differentiation, because mice that are nullizygous for these E2Fs have specific terminal-differentiation defects [37,38]. The pRb homologs, p107 and p130, can form repressor complexes in conjunction with E2F4 or E2F5 at most if not all the E2F-responsive gene promoters [9]. Vairo et al. [18] showed that p130 can interact with E2F4, and can actively repress E2F-regulated promoter activities. In our transgenic study, we found that when E2F5 and p130 were overexpressed in post-mitotic lens fiber cells, there was no inhibition of fiber cell differentiation or elongation. However, coexpression of E2F5 and p130 did significantly repress the cell cycle progression induced by overexpression of E2F1 or E2F3a. These results indicate that the activity of cell cycle “repressor” E2F5, if any, is dependent upon the tumor suppressor p130. Overexpression of p130 was previously found to arrest cancer cells in the G1 phase of the cell cycle and inhibit tumor growth [2,16,17]. Our transgenic observations are consistent with these previous studies. However, so far it is unclear whether p130 can inhibit cell cycle progression in the absence of E2F5. It was reported that in the absence of both E2F4 and E2F5, hypophosphorylated pocket proteins were unable to induce cell cycle exit [21], suggesting that these repressor E2Fs may be a necessary mediator for the pocket protein function. The precise growth suppressive mechanisms of p130 are not fully understood. One possibility is that it forms a repressive complex with E2F4 and E2F5, which then recruits HDAC1 to the E2F-regulated gene promoter and repress its activities [39]. Alternatively, since E2F1, E2F2, and E2F3 are capable of binding to p130 in two-hybrid systems or when overexpressed [40,41], the other possibility is that p130 binds directly to E2F1 and E2F3a to eliminate their transactivation.

**Figure 9.** Transcription of E2F1/E2F5/p130 transgenes at E15.5. In situ hybridizations were used to assay expression of the E2F1, E2F5 and p130 transgenes using SV40 (for E2F1), human E2F5 and mouse p130 riboprobes. Bright-field (A, C, E) and dark-field (B, D, F) images are shown. The transgenes were expressed specifically in lens fiber cells. Transcription signals of p130 (F) were much weaker than the E2F1 (B) and E2F5 (D) transgenes. Scale bars=500 μm.
ability. Nevertheless, how p130 interplays with E2Fs to function as a tumor suppressor remains to be determined.

**E2F5/p130 may be a useful tool in anti-cancer gene therapy:** Our in vivo transgenic results may have clinical significance. Mutations in the human gene encoding p130 are detected in diverse cancers including prostate, breast, and ovarian cancers [2]. Several studies have shown that p130 is downregulated in tumors at the transcriptional level rather than by posttranslational modifications [42-44], suggesting that loss of p130 expression could be an important event in development of tumors. For example, downregulation of p130 has been found in the genesis of neoplasms of the lung [43], breast [45], ovary [42], and non-Hodgkin’s lymphomas [46].

Development of mesothelioma [47] and AIDS-related lymphomas [46] is also related to inactivation of p130 function by viral oncoproteins. A previous study showed that retrovirus-mediated delivery of wild type p130 to the lung tumor cells could suppress tumor growth in vitro and in vivo [17], indicating a role of p130 in gene therapy. Our transgenic observations further confirm that p130, when overexpressed, can reduce inappropriate cell cycle reentry. Therefore, it may be a useful tool in gene therapy to inhibit tumor growth.

Overexpression of E2F1 or E2F3 has been shown to lead to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48]. E2F1 was found to increase transcription to both p53-dependent and – independent apoptosis in tissue culture cells [11,48].

In summary, we have used the transgenic mouse lens as a model system to study E2F and p130 activities. Although E2F5 is one of the “repressor” E2Fs, expression of E2F5 alone was not sufficient to interfere with cell cycle induction by the activator E2Fs. Overexpression of both E2F5 and p130 did not affect normal post-mitotic lens fiber cell differentiation. However, they did inhibit E2F-induced cell cycle reentry. Although the molecular basis of this phenomenon is not yet fully understood, our studies support the notion that p130 is an important cell cycle repressor, and therefore, may be useful for gene therapy in the treatment of tumors.

**ACKNOWLEDGMENTS**

This research was supported by NIH grants EY10448, EY10803, EY11348 (P.A.O.), EY015764 (Q.C.), and UHCO’s Core Grant (P30 EY007551).

**REFERENCES**

1. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24:2796-809. [PMID: 15838516]
2. Giordano A, Rossi A, Romano G, Bagella L. Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy. J Cell Physiol 2007; 213:403-6. [PMID: 17708530]
3. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, Berns A, te Riele H. Requirement for a functional Rb-l gene in murine development. Nature 1992; 359:328-30. [PMID: 1406937]
4. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992; 359:288-94. [PMID: 1406932]
5. Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T. Shared role of the pRb-related p130 and p107 proteins in limb development. Genes Dev 1996; 10:1633-44. [PMID: 8682294]
6. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev 1998; 12:2245-62. [PMID: 9694791]
7. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999; 97:53-61. [PMID: 10199402]
8. Hijnmans EM, Voorhoeve PM, Beijersbergen RL, van ’t Veer LJ, Bernards R. E2F5, a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 1995; 15:3082-9. [PMID: 7768080]
9. DeGregori J, Johnson DG. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. Curr Mol Med 2006; 6:739-48. [PMID: 17100600]
10. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005; 24:2810-26. [PMID: 15838517]
11. DeGregori J, Leo1ne G, Miron A, Jakoi L, Nevins JR. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 1998; 12:2120-30. [PMID: 9679057]
12. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS, Nevins JR. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 1998; 12:2120-30. [PMID: 9679057]
13. Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cells. Mol Cell Biol 2000; 20:5797-807. [PMID: 10913163]
14. Chen Q, Liang D, Yang T, Leone G, Overbeek PA. Distinct capacities of individual E2Fs to induce cell cycle reentry in postmitotic lens fiber cells of transgenic mice. Dev Neurosci 2004; 26:435-45. [PMID: 15855772]
15. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, Sun Y, Colburn N, Calabretta B, Giordano A. P130/pRb2
17. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minino C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, Tosi GM, Micheli P, Caputi M, Giordano GG, Giordano A. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 2000; 60:372-82. [PMID: 10667590]

18. Vairo G, Livingston DM, Ginsberg D. Functional interaction between E2F–4 and p130: Evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev 1995; 9:869-81. [PMID: 7705662]

19. Iavarone A, Massagué J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 1999; 19:916-22. [PMID: 9858615]

20. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000; 14:804-16. [PMID: 10766737]

21. Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM, Rempel RE. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 2000; 6:729-35. [PMID: 11030352]

22. CvekL A, Piatigorsky J. Lens development and crystallin gene expression: many roles for Pax-6. Bioessays 1996; 18:621-30. [PMID: 8760335]

23. Rampalli AM, Gao CY, Chauthaiwale VM, Zelenka PS. pRB and p107 regulate E2F activity during lens fiber cell differentiation. Oncogene 1998; 16:399-408. [PMID: 9467965]

24. Chen Q, Ash JD, Branton P, Fromm L, Overbeek PA. Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice. Oncogene 2002; 21:1028-37. [PMID: 11850820]

25. Fromm L, Shawlot W, Gunning K, Butel JS, Overbeek PA. The retinoblastoma protein-binding region of simian virus 40 large T antigen alters cell cycle regulation in lenses of transgenic mice. Mol Cell Biol 1994; 14:6743-54. [PMID: 7935393]

26. Pan H, Griend AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994; 8:1285-99. [PMID: 7926731]

27. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. P53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371:72-4. [PMID: 8072529]

28. Saavedra HI, Wu L, de Bruin A, Timmers C, Rosol TJ, Weinstein M, Robinson ML, Leone G. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ 2002; 13:215-25. [PMID: 12065245]

29. Chen Q, Hung F, Fromm L, Overbeek PA. Induction of cell cycle entry and cell death in postmitotic lens fiber cells by overexpression of E2F1 or E2F2. Invest Ophthalmol Vis Sci 2000; 41:4223-31. [PMID: 11095619]

30. Reneker LW, Chen Q, Bloch A, Xie L, Schuster G, Overbeek PA. Chick delta1-crystallin enhancer influences mouse alphaA-crystallin promoter activity in transgenic mice. Invest Ophthalmol Vis Sci 2004; 45:4083-90. [PMID: 15505059]

31. Hogan BF, Costantini F, Lacy E, Beddington R. Manipulating the Mouse Embryo: 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

32. Taketo M, Schroeder AC, Moobaten LE. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 1991; 88:2065-9. [PMID: 1848692]

33. Fromm L, Overbeek PA. Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein. Oncogene 1996; 12:69-75. [PMID: 8552401]

34. Araki K, Nakajima Y, Eto K, Ikeda MA. Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene 2003; 22:7632-41. [PMID: 14576826]

35. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3:11-20. [PMID: 11823794]

36. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 3:11-20. [PMID: 11823794]

37. Helmbold H, Deppert W, Bohn W. Regulation of cellular senescence by Rb2/p130. Oncogene 2006; 25:5257-62. [PMID: 16936745]

38. Araki K, Nakajima Y, Eto K, Ikeda MA. Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter. Oncogene 2003; 22:7632-41. [PMID: 14576826]

39. Kelso GM, Livingston DM, Ginsberg D. Functional interaction between E2F and pRB family members. Genes Dev 1995; 9:869-81. [PMID: 7705662]

40. Iavarone A, Massagué J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 1999; 19:916-22. [PMID: 9858615]

41. Takahashi Y, Rayman JB, Dynlacht BD. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 2000; 14:804-16. [PMID: 10766737]

42. Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM, Rempel RE. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 2000; 6:729-35. [PMID: 11030352]

43. CvekL A, Piatigorsky J. Lens development and crystallin gene expression: many roles for Pax-6. Bioessays 1996; 18:621-30. [PMID: 8760335]

44. Rampalli AM, Gao CY, Chauthaiwale VM, Zelenka PS. pRB and p107 regulate E2F activity during lens fiber cell differentiation. Oncogene 1998; 16:399-408. [PMID: 9467965]

45. Chen Q, Ash JD, Branton P, Fromm L, Overbeek PA. Inhibition of crystallin expression and induction of apoptosis by lens-specific E1A expression in transgenic mice. Oncogene 2002; 21:1028-37. [PMID: 11850820]

46. Fromm L, Shawlot W, Gunning K, Butel JS, Overbeek PA. The retinoblastoma protein-binding region of simian virus 40 large T antigen alters cell cycle regulation in lenses of transgenic mice. Mol Cell Biol 1994; 14:6743-54. [PMID: 7935393]

47. Pan H, Griend AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994; 8:1285-99. [PMID: 7926731]

48. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. P53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371:72-4. [PMID: 8072529]

49. Saavedra HI, Wu L, de Bruin A, Timmers C, Rosol TJ, Weinstein M, Robinson ML, Leone G. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ 2002; 13:215-25. [PMID: 12065245]

50. Chen Q, Hung F, Fromm L, Overbeek PA. Induction of cell cycle entry and cell death in postmitotic lens fiber cells by overexpression of E2F1 or E2F2. Invest Ophthalmol Vis Sci 2000; 41:4223-31. [PMID: 11095619]
alpha in breast cancer. Oncogene 2003; 22:3511-7. [PMID: 12789259]

46. Lazzi S, Bellan C, De Falco G, Cinti C, Ferrari F, Nyongo A, Claudio PP, Tosi GM, Vatti R, Gloghini A, Carbone A, Giordano A, Leoncini L, Tosi P. Expression of RB2/p130 tumor-suppressor gene in AIDS-related non-Hodgkin's lymphomas: implications for disease pathogenesis. Hum Pathol 2002; 33:723-31. [PMID: 12196924]

47. Mutti L, De Luca A, Claudio PP, Convertino G, Carbone M, Giordano A. Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. Dev Biol Stand 1998; 94:47-53. [PMID: 9776225]

48. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr. Role for the p53 homologue p73 in E2F–1-induced apoptosis. Nature 2000; 407:645-8. [PMID: 11034215]

49. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9:113-8. [PMID: 9486847]